Background: Since anxiety and depressive disorders often recur, self-management competencies are crucial for improving the long-term course of anxiety and depressive disorders. However, few relapse prevention programmes are available that focus on improving self-management. E-health combined with personal contact with a mental health professional in general practice might be a promising approach for relapse prevention. In this protocol, the GET READY (Guided E-healTh for RElapse prevention in Anxiety and Depression) study will be described in which a relapse prevention programme is developed, implemented and evaluated. The aim of the study is to determine patients' usage of the programme and the associated course of their symptoms, to examine barriers and facilitators of implementation, and to assess patients' satisfaction with the programme.
Methods: Participants are discharged from mental healthcare services, and are in complete or partial remission. They receive access to an E-health platform, combined with regular contact with a mental health professional in general practices. Online questionnaires will be completed at baseline and after 3, 6 and 9 months. Also, semi-structured qualitative individual interviews and focus group interviews will be conducted with patients and mental health professionals.
Discussion: This mixed-methods observational cohort study will provide insights into the use of a relapse prevention programme in relation to the occurrence of symptoms, as well as in its implementation and evaluation. Using the results of this study, the relapse prevention programme can be adapted in accordance with the needs of patients and mental health professionals. If this programme is shown to be acceptable, a randomized controlled trial may be conducted to test its efficacy.
Trial Registration: Retrospectively registered in the Netherlands Trial Register ( NTR7574 ; 25 October 2018).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371559 | PMC |
| http://dx.doi.org/10.1186/s12888-019-2034-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study.
Lancet Psychiatry
February 2025
Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland; Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Neuroscience Center, University of Helsinki, Helsinki, Finland.
Background: The best pharmacological treatment practices for relapse prevention in patients with first-episode schizophrenia are unclear. We aimed to assess different treatment strategies used before and after the first relapse, and their associations with subsequent relapse risk.
Methods: In this population-based cohort study, we enrolled individuals (aged ≤45 years) with first-episode schizophrenia who were hospitalised and subsequently relapsed between 1996 and 2014 from the nationwide Finnish Hospital Discharge Register.
Surgical Helmet Systems do not reduce the incidence of periprosthetic joint infections in elbow arthroplasty. Results from the New Zealand National Joint Registry 2000-2023.
J Shoulder Elbow Surg
January 2025
Department of Orthopaedic Surgery, North Shore Hospital, Takapuna, Auckland, New Zealand; Department of Surgery, University of Auckland, Grafton, Auckland, New Zealand.
Hypothesis And Background: The incidence of prosthetic joint infection (PJI) remains high following elbow arthroplasty procedures. The purpose of this study was to investigate whether Surgical Helmet Systems (SHS) reduce rates of PJI after elbow arthroplasty in a population-based registry study over a consecutive 23-year period. We hypothesized SHS would reduce the incidence of PJI compared with conventional surgical gowns following elbow arthroplasty surgery.
View Article and Find Full Text PDFRespiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
Lancet Infect Dis
January 2025
Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA, USA.
Background: New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information on the real-world effectiveness of these vaccines is needed.
Methods: We used electronic health records in the Veterans Health Administration to emulate a target trial comparing a single dose of a recombinant stabilised prefusion F protein RSV vaccine versus no vaccination among veterans aged 60 years and older.
Spatiotemporal estimates of anthropogenic NO emissions across China during 2015-2022 using a deep learning model.
J Hazard Mater
January 2025
Key Laboratory of Geographic Information Science of the Ministry of Education, School of Geographic Sciences, East China Normal University, Shanghai 200241, PR China; Institute of Eco-Chongming (IEC), 20 Cuiniao Road, Chenjia Town, Chongming District, Shanghai 202162, PR China. Electronic address:
As one of the significant air pollutants, nitrogen oxides (NO = NO + NO) not only pose a great threat to human health, but also contribute to the formation of secondary pollutants such as ozone and nitrate particles. Due to substantial uncertainties in bottom-up emission inventories, simulated concentrations of air pollutants using GEOS-Chem model often largely biased from those of ground-level observations. To address this issue, we developed a new deep learning model to simulate the inverse process of the GEOS-Chem model.
View Article and Find Full Text PDFPersistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.
PLoS Med
January 2025
Division of Infectious Diseases, Department of Medicine II, Medical Centre and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Background: Self-reported health problems following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are common and often include relatively non-specific complaints such as fatigue, exertional dyspnoea, concentration or memory disturbance and sleep problems. The long-term prognosis of such post-acute sequelae of COVID-19/post-COVID-19 syndrome (PCS) is unknown, and data finding and correlating organ dysfunction and pathology with self-reported symptoms in patients with non-recovery from PCS is scarce. We wanted to describe clinical characteristics and diagnostic findings among patients with PCS persisting for >1 year and assessed risk factors for PCS persistence versus improvement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!